Evidence map›Paper›PMID 40833473›Full record

ReviewClinical and experimental nephrology2025

Epigenetic memories induced by hypoxia in AKI-to-CKD transition.

Giyoung Kwoun, Masaomi Nangaku, Imari Mimura

Abstract readReview
In one paragraph

Review in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Hypoxic adaptation theory of cancer.Frontiers in cell and developmental biology · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giyoung KwounDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Imari MimuraDivision of Nephrology and Endocrinology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. imimura@m.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-3454-5127

Funding

Chugai Pharmaceutical SRG2023Japan Society for the Promotion of Science 25K11537
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a global health burden associated with increasing mortality rates. Aging populations and declining fertility rates exacerbate this issue, particularly in countries such as Japan. Acute kidney injury (AKI) was previously considered temporary and reversible condition. However, in recent years, multiple studies on kidney diseases have shown that AKI survivors are at an increased risk of developing CKD. During the AKI-to-CKD transition, a subset of AKI-induced epigenetic alterations persists in cells, potentially driving the progression of tubulointerstitial fibrosis. Therefore, targeting epigenetic mechanisms may represent a promising therapeutic approach for preventing AKI-to-CKD transition. Among the epigenetic mechnisms involved, "hypoxic memory" plays a crucial role in this transition by inducing persistent epigenetic changes. Hypoxic memory induces DNA methylation, histone modification, changes in chromatin conformation, and long non-codingRNA (lncRNA) expression. Herein, we review the latest evidence on epigenetic memory in the AKI-to-CKD transition, identifying that the detailed mechanisms of epigenetic memory and temporal specificity are crucial for developing effective treatments.

Indexed as

Acute Kidney InjuryEpigenesis, GeneticHypoxiaRenal Insufficiency, ChronicAnimalsDisease ProgressionDNA MethylationHumansRNA, Long NoncodingRNA, Long NoncodingAKI-to-CKD transitionHistoneHypoxic memory

Identifiers

PMID40833473
PMCPMC12660417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.